ArticleBritish journal of pharmacology2015

PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

L Mestre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.